Free
Articles  |   May 2012
The Cell and Molecular Biology of Glaucoma: Common Neurodegenerative Pathways and Relevance to Glaucoma
Author Affiliations & Notes
  • Stuart J. McKinnon
    From the Departments of Ophthalmology and Neurobiology, Duke University Medical Center, Durham, North Carolina.
  • Corresponding author: Stuart J. McKinnon, Duke University Medical Center, Box 3802, Erwin Road, Durham, NC 27710; stuart.mckinnon@duke.edu
Investigative Ophthalmology & Visual Science May 2012, Vol.53, 2485-2487. doi:10.1167/iovs.12-9483j
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Stuart J. McKinnon; The Cell and Molecular Biology of Glaucoma: Common Neurodegenerative Pathways and Relevance to Glaucoma. Invest. Ophthalmol. Vis. Sci. 2012;53(5):2485-2487. doi: 10.1167/iovs.12-9483j.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Recent work in our laboratory has shown that glaucoma and Alzheimer's disease (AD) share similar molecular and cellular pathways that may contribute to neuronal loss in glaucoma. 1 Investigating these shared pathways will yield valuable clues to aid in rational drug design for the treatment of glaucoma. 
Classification of Chronic Neurodegenerations
Most neurodegenerations can be classified into one of two categories: Specific genetic mutations cause autosomal dominant (“familial”), early-onset forms of AD, Huntington's disease (HD), and Parkinson's disease (PD). Fortunately, the incidence of these familial types of neurodegeneration is low, comprising less than 10% of total cases of AD, HD, and PD. These mutations have been exploited to create transgenic mouse models that have greatly aided in the understanding of the pathobiology of these diseases. The more prevalent category of neurodegenerations includes AD, PD, and amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease). These sporadic diseases manifest in the later decades of life and are not associated with specific gene mutations, as are the familial forms of the diseases—facts that closely parallel those in open-angle glaucoma. Mounting evidence shows that late-onset neurodegenerations are characterized by a combination of genetic susceptibility and environmental exposure with mechanisms that overlap those in the familial or early-onset forms of the disease. 
Alzheimer's Disease
AD is a progressive, debilitating neurodegeneration and is the most common form of dementia. It causes loss of neurons in the hippocampus and cerebral cortex, leading to short-term memory loss. It is characterized by the formation of aggregated proteins composed of amyloid-β, known as amyloid plaques, and neurofibrillary tangles, composed of hyperphosphorylated tau protein. 2 Amyloid-β is cleaved from the membrane-bound protein amyloid precursor protein (APP) by enzymes termed secretases. The pathologic forms of amyloid-β are cleaved by β- and γ-secretases; these are currently target components of drugs under development for the treatment of AD. A third secretase, the α subtype, cleaves APP to form a soluble form that is important in neuronal survival and synaptic maintenance. 
APP is the most abundant protein in the optic nerve. It is rapidly transported in the optic nerve in small vesicles and is transferred to the axon plasma membrane and synapses. 3 The incidence of glaucoma is significantly higher in AD patients than in age-matched controls: 26% versus 5% in a German population 4 and 24% versus 9% in a Japanese population. 5 Furthermore, progression of visual field defects is accelerated in patients with open-angle glaucoma and AD versus patients with open-angle glaucoma without AD. 6 We have shown that APP is abnormally processed, and neurotoxic amyloid-β species are upregulated in the retina of rats 7 and mice 8 exposed to chronically elevated eye pressure. Hyperphosphorylated tau protein has also been detected in the retinas of glaucoma patients. 9 Glaucoma and AD are characterized by synaptic degeneration in the brain, which implies that it is not just a disease of the eye, but of the brain as well. 10  
Memantine, a treatment approved by the U.S. Food and Drug Administration for AD, has been used in a clinical study for the treatment of human glaucoma. Unfortunately, the clinical endpoints (preservation of visual fields) for the study were not reached, probably due to an ineffective mechanism of action. 11 However, directly targeting the formation of amyloid-β has shown promise in preserving retinal ganglion cells (RGCs) in a rat glaucoma model. 12  
Parkinson's Disease
PD is the most common neurodegenerative movement disorder, caused by loss of dopaminergic neurons in the substantia nigra of the brain. 2 It is characterized by slowness of movement, difficulty in walking, rigidity, and shaking. As with AD, cognitive and behavioral problems and dementia occur in advanced stages of PD. Hereditary forms of PD show mutations in α-synuclein and phosphatase and tensin homolog (PTEN), and pathology shows eosinophilic cytoplasmic inclusions of fibrillar, misfolded proteins termed Lewy bodies. 
The synucleins are a family of proteins with unknown function, but a link between γ-synuclein and PD and other synucleinopathies has been established. γ-Synuclein has been noted to be deposited in a specific area of the optic nerve head where myelin begins to be expressed. A recent study has shown that optic nerve astrocytes digest and process RGC axonal processes, suggesting that optic nerve head astrocytes are important for normal maintenance of RGCs. Axonal material found inside these astrocytes contained a protease-resistant form of γ-synuclein, possibly contributing to the loss of RGCs in glaucoma. 13  
PTEN is a negative regulator of the mammalian target of rapamycin (mTOR) pathway, 2 and in wild-type adult mice, mTOR activity is suppressed and protein synthesis is impaired in axotomized RGCs. 14 Of note, deletion of PTEN promotes axon regeneration after optic nerve crush in mice, and the manipulation of PTEN and mTOR pathways is an exciting new therapeutic approach to promoting axon regeneration after central nervous system injury, both in the eye and in the brain and spinal cord. 
Amyotrophic Lateral Sclerosis
ALS is a progressive, fatal motor neuron disease caused by the degeneration of neurons located in the ventral horn of the spinal cord and the cortical neurons that provide their afferent input. It is characterized by rapidly progressive weakness, muscle atrophy, fasciculations, spasticity, dysarthria, dysphagia, and respiratory compromise. 2 Mutations in Cu/Zn superoxide dismutase (SOD), a potent antioxidant enzyme, cause 2% to 3% of ALS cases. Oxidative stress and the expression of reactive oxygen species have been linked to the pathogenesis of glaucoma, 15 and the use of antioxidants such as SOD analogues represents a promising therapeutic approach to the treatment of glaucoma. 
Neuroinflammation
Neuroinflammation is rapidly emerging as a major contributor to the development of chronic neurodegenerations such as AD and PD, as well as glaucoma. Complement proteins are part of the immune system that aid antibodies and phagocytic cells in clearing pathogens. C1q is the first element in the classic complement activation pathway, and it activates several proteases (C1r, C1s, C2, C3, and C4) that initiate opsonization and anaphylactic reactions that attract phagocytic cells. Increased neuronal C1q expression occurs in AD, 16 and C1q has been shown to be upregulated in mouse and monkey glaucoma models. 17 In a recent study involving a model of inherited mouse glaucoma, the normal developmental mechanism of complement-mediated synapse elimination was aberrantly reactivated in retinal astrocytes. 18 The authors conjectured that C1q tags retinal synapses for early elimination and drives dendritic atrophy and axon degeneration that occur in glaucoma. 
Tumor necrosis factor (TNF)-α is an inflammatory cytokine, and its receptors TNFR1a and TNFR1b have been noted to be upregulated in the retinas of glaucoma patients. 19 In a study of a mouse glaucoma model of elevated IOP, the absence (knockout) of the TNFR1b gene afforded robust neuroprotection of RGCs and their axons. Serum amyloid A is an acute-phase marker of inflammation and infection, and gene-profiling studies of glaucoma have shown upregulation of serum amyloid A in the trabecular meshwork and retina of glaucoma patients. 20,21  
Micro-RNA Regulation of Gene Expression in Chronic Neurodegenerations
Because glaucoma and other chronic neurodegenerations share common genetic mechanisms, it is critical to understand how the expression of genes are regulated in the retina and optic nerve in glaucoma, as this knowledge may enable rational drug design for therapeutic intervention. Recent investigations into the regulation of gene expression have focused on micro (mi)RNAs, which are short, endogenously expressed, noncoding RNAs that bind to the 3′ untranslated region of messenger RNA, targeting it for downregulation or degradation. 22  
Several laboratories have shown significant changes in expression of some miRNAs in the brains of AD patients. Downregulation of these miRNAs is believed to contribute to increased production and accumulation of amyloid-β in these brains. Other miRNAs dysregulated in AD, such as miR-27b, -34a, and -146a, have been hypothesized to contribute to AD pathogenesis by increasing oxidative stress and inducing inflammation. 23 In a recent report, human astrocytes from normal individuals were cultured in vitro and treated with interleukin-6 to induce astrogliosis, a detrimental cellular process that occurs in AD brains. Levels of miRNAs were assayed, and miRNA-125b was noted to be upregulated. When miRNA-125b activity was repressed with antisense miRNA-125b, glial cell proliferation and increased expression of CDKN2A (cyclin-dependent kinase inhibitor 2A) were found. CDKN2A is a miRNA-125b target and negative regulator of cell growth. CDKN2A downregulation has been noted in advanced AD and Down's syndrome brains, disorders associated with astrogliosis. The authors reasoned that miRNA-125b upregulation contributes to cell cycle defects and the astrogliosis that is characteristic of neurodegeneration. 24 This finding may be of major importance, given recent reports of a significant association between polymorphisms in CDKN2BAS and open-angle glaucoma. 25,26  
Given the relationship between AD and glaucoma, we hypothesize that in glaucoma, the retina and optic nerve experience changes in miRNA expression similar to those reported in the brains of AD patients. The observation of changes in expression of specific miRNAs associated with glaucoma should be useful in elucidating the pathogenic mechanisms involved in the loss of RGCs and could identify novel therapeutic targets. 
Summary
Glaucoma is an age-related, chronic neurodegeneration of the optic nerve. The molecular and cellular pathologies that characterize the disease are shared by other chronic neurodegenerations such as AD, PD, and ALS. Therapies directed at treating chronic neurodegenerations have potential for use in treating glaucoma; conversely, therapies that are successful in treating glaucoma could be used in treating other chronic neurodegenerations. The following are targets for therapeutic intervention in chronic neurodegenerations and glaucoma:
  •  
    Axonal transport and integrity
  •  
    Autophagy and lysosomes
  •  
    DNA damage and repair
  •  
    Excitotoxicity and oxidative stress
  •  
    Gene regulation and miRNA
  •  
    Mitochondrial function
  •  
    Neuroinflammation
  •  
    Programmed cell death (apoptosis)
  •  
    Protein folding and chaperones
  •  
    Synaptic function
  •  
    Ubiquitination and proteasome function
Finally, many of the molecular and cellular pathologies that characterize chronic neurodegenerations could be detected first in the eye, leading to earlier diagnosis and more effective treatments. 
Footnotes
 Disclosure: S.J. McKinnon, Merz Pharmaceuticals, GmbH (F, C, R); Pfizer, Inc. (F); Allergan, Inc. (C, R)
References
McKinnon SJ . Glaucoma: ocular Alzheimer's disease? Front Biosci. 2003;8:s1140–s1156. [CrossRef] [PubMed]
Bossy-Wetzel E Schwarzenbacher R Lipton SA . Molecular pathways to neurodegeneration. Nat Med. 2004;10(suppl):S2–S9. [CrossRef] [PubMed]
Morin PJ Abraham CR Amaratunga A . Amyloid precursor protein is synthesized by retinal ganglion cells, rapidly transported to the optic nerve plasma membrane and nerve terminals, and metabolized. J Neurochem. 1993;61:464–473. [CrossRef] [PubMed]
Bayer AU Ferrari F Erb C . High occurrence rate of glaucoma among patients with Alzheimer's disease. Eur Neurol. 2002;47:165–168. [CrossRef] [PubMed]
Tamura H Kawakami H Kanamoto T . High frequency of open-angle glaucoma in Japanese patients with Alzheimer's disease. J Neurol Sci. 2006;246:79–83. [CrossRef] [PubMed]
Bayer AU Ferrari F . Severe progression of glaucomatous optic neuropathy in patients with Alzheimer's disease. Eye. 2002;16:209–212. [CrossRef] [PubMed]
McKinnon SJ Lehman DM Kerrigan-Baumrind LA . Caspase activation and amyloid precursor protein cleavage in rat ocular hypertension. Invest Ophthalmol Vis Sci. 2002;43:1077–1087. [PubMed]
Kipfer-Kauer A McKinnon SJ Frueh BE Goldblum D . Distribution of amyloid precursor protein and amyloid-beta in ocular hypertensive C57BL/6 mouse eyes. Curr Eye Res. 2010;35:828–834. [CrossRef] [PubMed]
Gupta N Fong J Ang LC Yucel YH . Retinal tau pathology in human glaucomas. Can J Ophthalmol. 2008;43:53–60. [CrossRef] [PubMed]
Gupta N Yucel YH . Brain changes in glaucoma. Eur J Ophthalmol. 2003;13(suppl 3):S32–S35. [PubMed]
Osborne NN . Recent clinical findings with memantine should not mean that the idea of neuroprotection in glaucoma is abandoned. Acta Ophthalmol. 2009;87:450–454. [CrossRef] [PubMed]
Guo L Salt TE Luong V . Targeting amyloid-beta in glaucoma treatment. Proc Natl Acad Sci USA. 2007;104:13444–13449. [CrossRef] [PubMed]
Nguyen JV Soto I Kim KY . Myelination transition zone astrocytes are constitutively phagocytic and have synuclein dependent reactivity in glaucoma. Proc Natl Acad Sci USA. 2011;108:1176–1181. [CrossRef] [PubMed]
Verma P Chierzi S Codd AM . Axonal protein synthesis and degradation are necessary for efficient growth cone regeneration. J Neurosci. 2005;25:331–342. [CrossRef] [PubMed]
Tezel G . Oxidative stress in glaucomatous neurodegeneration: mechanisms and consequences. Prog Retin Eye Res. 2006;25:490–513. [CrossRef] [PubMed]
Fonseca MI Chu SH Berci AM . Contribution of complement activation pathways to neuropathology differs among mouse models of Alzheimer's disease. J Neuroinflammation. 2011;8:4. [CrossRef] [PubMed]
Stasi K Nagel D Yang X . Complement component 1Q (C1Q) upregulation in retina of murine, primate, and human glaucomatous eyes. Invest Ophthalmol Vis Sci. 2006;47:1024–1029. [CrossRef] [PubMed]
Stevens B Allen NJ Vazquez LE . The classical complement cascade mediates CNS synapse elimination. Cell. 2007;131:1164–1178. [CrossRef] [PubMed]
Tezel G . TNF-alpha signaling in glaucomatous neurodegeneration. Prog Brain Res. 2008;173:409–421. [PubMed]
Walsh MM Yi H Friedman J . Gene and protein expression pilot profiling and biomarkers in an experimental mouse model of hypertensive glaucoma. Exp Biol Med. 2009;234:918–930. [CrossRef]
Wang WH McNatt LG Pang IH . Increased expression of serum amyloid A in glaucoma and its effect on intraocular pressure. Invest Ophthalmol Vis Sci. 2008;49:1916–1923. [CrossRef] [PubMed]
Du L Pertsemlidis A . Cancer and neurodegenerative disorders: pathogenic convergence through microRNA regulation. J Mol Cell Biol. 2011;3:176–180. [CrossRef] [PubMed]
Cogswell JP Ward J Taylor IA . Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways. J Alzheimers Dis. 2008;14:27–41. [PubMed]
Pogue AI Cui JG Li YY Zhao Y Culicchia F Lukiw WJ . Micro RNA-125b (miRNA-125b) function in astrogliosis and glial cell proliferation. Neurosci Lett. 2010;476:18–22. [CrossRef] [PubMed]
Fan BJ Wang DY Pasquale LR Haines JL Wiggs JL . Genetic variants associated with optic nerve vertical cup-to-disc ratio are risk factors for primary open angle glaucoma in a US Caucasian population. Invest Ophthalmol Vis Sci. 2011;52(3):1788–1792. [CrossRef] [PubMed]
Burdon KP Macgregor S Hewitt AW . Genome-wide association study identifies susceptibility loci for open angle glaucoma at TMCO1 and CDKN2B-AS1. Nat Genet. 2011;43(6):574–578. [CrossRef] [PubMed]
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×